.png)
Our mission is to develop and deliver innovative therapies that improve the lives of adults with cancer. Our drug, COSELA®(trilaciclib), is FDA-approved for patients with extensive-stage small-cell lung cancer, and we are currently evaluating COSELA in combination with multiple therapies for colorectal, breast, and bladder cancers.
